It might be seen as reckless to challenge to create single-agents for the treatment of both type 1 diabetes caused by the destruction of the Langerhans cells in pancreas by excessive autoimmunity, and type 2 diabetes caused by the obesity. However, we hypothesized that retinoid X receptor (RXR) agonists, which are researched for the treatment of type 2 diabetes, will also act as novel anti-type 1 diabetes drugs based on the regulatory T cell (Treg) inducing activity which plays a key role on the immunotolerance maintenance. RXRs function as homo-or . In this symposium, Treg inducing activity and efficacy to diabetes model mice by our RXR agonists will be presented.
